Scarica l'app Stockscreener
1.82
1.68%
0.03
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan
Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
William Blair Predicts Skye Bioscience Q1 Earnings - Defense World
Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World
Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus
Skye Bioscience reports promising obesity treatment study - Investing.com
Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire
Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider
Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan
Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus
Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan
Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World
Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire
Let's Tokyo! WestJet bolsters connectivity between Calgary and Japan with new daily year-round service - The Globe and Mail
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN
Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat
Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter
Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada
Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World
Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World
Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):